Uveal Melanoma — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardMelanoma & SkinUveal MelanomaSCE Medical Oncology

A fit patient has newly diagnosed unresectable metastatic uveal melanoma. Before selecting tebentafusp, which single test is indispensable because it defines whether the drug can engage its gp100 peptide target?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — HLA-A*02:01 typing

Explanation lettering: D = shown as A · A = shown as B · E = shown as D · B = shown as E

C is correct because tebentafusp is restricted to HLA-A*02:01-positive disease. A is relevant to cutaneous melanoma but not tebentafusp eligibility; B does not select tebentafusp; D informs inherited-risk counselling in selected families; E helps biology or diagnosis but does not replace HLA typing.

Reference: NICE TA1027 tebentafusp for advanced uveal melanoma (Published 9 January 2025): https://www.nice.org.uk/guidance/ta1027/chapter/1-Recommendation